data + articles · 3 listed
newest 2001spec sheet6 rows
Gacyclidine (GK-11) is a phencyclidine derivative built for an entirely different job than PCP or ketamine ever had: not anesthesia or recreational dissociation, but neuroprotection after acute spinal cord injury. French chemist Jean-Marie Kamenka's PCP-analog work fed into development by Beaufour-Ipsen through the 1990s, producing a compound with roughly 100x higher affinity than PCP itself at the same NMDA channel binding site. It moved into human testing for acute spinal cord injury and was also explored for protecting the inner ear during cochlear trauma, while French defense-affiliated researchers separately studied it as a possible countermeasure for nerve-agent-induced seizures. Development for CNS trauma quietly stalled in the early 2000s as the whole NMDA-antagonist neuroprotectant class collapsed under disappointing trial results and psychotomimetic side effects, leaving gacyclidine as one of the more unusual dead ends in the ketamine/PCP family tree.
- much higher NMDA channel affinity than PCP itself
- clear neuroprotective effect in animal spinal cord injury models
- explored for inner-ear protection during cochlear trauma
- dissociative/psychotomimetic effects at higher doses
- sedation
- Gacyclidine binds the NMDA channel's PCP site roughly 100x more tightly than PCP itself.
- Beyond spinal cord injury, French defense-affiliated researchers studied it as a potential treatment for seizures caused by nerve-agent (organophosphate) poisoning.
Mechanism
Non-competitive channel blocker in the phencyclidine (PCP) structural family, with substantially higher binding affinity than PCP at the same channel site, intended to block excitotoxic calcium influx after acute injury.
Safetyrisks and cautions, not medical advice
Human exposure was always intravenous, always in a hospital, and always within hours of a head or spinal injury; that is the entire context of its safety record. In a randomised placebo-controlled brain injury trial of about fifty patients given two infusions, 181 serious adverse events were logged across the cohort and only ten judged drug-related, twelve patients died with none attributed to the drug, and safety labs and ECGs showed nothing relevant. Being PCP-family chemistry, dissociation and sedation appear as the dose climbs. What does not exist is any oral form, any repeat-dosing data, or any exposure in healthy people.
History
Developed by the French firm Beaufour-Ipsen through the 1990s, building on PCP-analog chemistry; tested in humans for acute spinal cord injury and studied preclinically for cochlear/inner-ear protection; development for CNS trauma stalled in the early 2000s alongside the broader collapse of NMDA-antagonist neuroprotectants.
Subjective profileweighing the evidence above
A rare case of a PCP-class dissociative engineered deliberately away from recreational use, toward trauma medicine, that still couldn't outrun the class-wide failure of NMDA-blocker neuroprotection.
Resources
This entry is here for reference.
Research
- 1.Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats
- 2.Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury
- 3.Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor
3 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is gacyclidine the same as PCP?
It's a chemical analog from the same phencyclidine chemistry lineage (Kamenka's PCP-analog work), but it was engineered purely as a research and neuroprotective drug, never developed or used recreationally.
What was it actually used for in trials?
Acute spinal cord injury was its main human application, with additional preclinical interest in protecting the inner ear from cochlear trauma and, separately, as a potential countermeasure against nerve-agent-induced seizures.
Limitations of the evidence
- no confirmed clinical efficacy in human CNS trauma trials
Adverse effects
- dissociative/psychotomimetic effects at higher doses
- sedation